Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Vedovati, MC; Giustozzi, M; Munoz, A; Bertoletti, L; Cohen, AT; Klok, FA; Connors, JM; Bauersachs, R; Brenner, B; Campanini, M; Becattini, C; Agnelli, G.

Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism

EUROPEAN JOURNAL OF INTERNAL MEDICINE. 2023; 112: 29-36 Nº de citas: 33 [doi:10.1016/j.ejim.2023.02.003]

Bueno-Muino, C; Echavarria, I; Lopez-Tarruella, S; Roche-Molina, M; del Monte-Millan, M; Massarrah, T; Jerez, Y; de la Pena, FA; Garcia-Saenz, JA; Moreno, F; Rodriguez-Lescure, A; Malon-Gimenez, D; Garcia, AIB; Marin-Aguilera, M; Galvan, P; Braso-Maristany, F; Waks, AG; Tolaney, SM; Mittendorf, EA; Vivancos, A; Villagrasa, P; Parker, JS; Perou, CM; Pare, L; Villacampa, G; Prat, A; Martin, M.

Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab

JAMA Oncology. 2023; 9(6): 841-846 Nº de citas: 21 [doi:10.1001/jamaoncol.2023.0187]

Ruiz-Briones, P; Escudero-Vilaplana, V; Collado-Borrell, R; Vicente-Valor, J; Alvarez, R; Villanueva-Bueno, C; Narrillos-Moraza, A; Herranz, A; Sanjurjo, M.

Possible heart failure caused by osimertinib in a lung cancer patient

JOURNAL OF ONCOLOGY PHARMACY PRACTICE. 2023; 29(4): 1015-1020 Nº de citas: 4 [doi:10.1177/10781552221143787]

Zatarain-Nicolas, E; Martin, P; Rodas, IM; Virizuela, J; Garcia, AM; Mitroi, C; Sales, JC; Barrios, V; Sanchez-Cabo, F; Ibanez, B; Carpeno, JD; Fernandez, TL.

Cardiovascular toxicity of checkpoint inhibitors: review of associated toxicity and design of the Spanish Immunotherapy Registry of Cardiovascular Toxicity

CLINICAL & TRANSLATIONAL ONCOLOGY. 2023; 25(11): 3073-3085 Nº de citas: 3 [doi:10.1007/s12094-023-03217-2]

Verso, M; Munoz, A; Connors, JM.

Ambulatory cancer patients: who should definitely receive antithrombotic prophylaxis and who should never receive

INTERNAL AND EMERGENCY MEDICINE. 2023; 18(6): 1619-1634 Nº de citas: 3 [doi:10.1007/s11739-023-03306-8]

Capdevila, J; Hernando, J; Teule, A; Lopez, C; Garcia-Carbonero, R; Benavent, M; Custodio, A; Garcia-Alvarez, A; Cubillo, A; Alonso, V; Carmona-Bayonas, A; Alonso-Gordoa, T; Crespo, G; Jimenez-Fonseca, P; Blanco, M; Viudez, A; La Casta, A; Sevilla, I; Segura, A; Llanos, M; Landolfi, S; Nuciforo, P; Manzano, JL.

Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin

Nature Communications. 2023; 14(1): Nº de citas: 34 [doi:10.1038/s41467-023-38611-5]

Sanchez-Canovas, M; Jimenez-Fonseca, P; Garay, DF; Solis, MC; Elia, DC; Salvans, EC; Vacas, ID; Sanchez, DG; Montes, AF; Gimenez, RM; de Tejada, MBG; Arrula, VA; Lopez, SS; Candelera, RO; Cendra, CS; de la Pena, MJ; Munoz, DM; Sarmiento, MO; de Castro, EM; Escobar, IG; Vidal, AB; Moran, LO; Martin, AJM; Bayona, RS; Ortiz, MJM; de la Pena, FA; Vicente, V; Carmona-Bayonas, A.

Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study

PLoS One. 2023; 18(5): Nº de citas: 2 [doi:10.1371/journal.pone.0266305]

Garcia-Saenz, JA; Blancas, I; Echavarria, I; Hinojo, C; Margeli, M; Moreno, F; Pernas, S; Cajal, TRY; Ribelles, N; Bellet, M.

SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (2022)

CLINICAL & TRANSLATIONAL ONCOLOGY. 2023; 25(9): 2665-2678 Nº de citas: 5 [doi:10.1007/s12094-023-03203-8]

Gravalos, C; Pereira, F; Vera, R; Arjona-Sanchez, A; Losa, F; Ramos, I; Garcia-Alfonso, P; Gonzalez-Bayon, L; Cascales-Campos, PA; Aranda, E.

Recommendations for the optimal management of peritoneal metastases in patients with colorectal cancer: a TTD and GECOP-SEOQ expert consensus statement

CLINICAL & TRANSLATIONAL ONCOLOGY. 2023; 25(12): 3378-3394 Nº de citas: 2 [doi:10.1007/s12094-023-03204-7]

Montes, AF; Alonso, V; Aranda, E; Elez, E; Alfonso, PG; Gravalos, C; Maurel, J; Vera, R; Vidal, R; Aparicio, J.

SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022)

CLINICAL & TRANSLATIONAL ONCOLOGY. 2023; 25(9): 2718-2731 Nº de citas: 6 [doi:10.1007/s12094-023-03199-1]

Serrano, C; Alvarez, R; Carrasco, JA; Marquina, G; Martinez-Garcia, J; Martinez-Marin, V; Sala, MA; Sebio, A; Sevilla, I; Martin-Broto, J.

SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)

CLINICAL & TRANSLATIONAL ONCOLOGY. 2023; 25(9): 2707-2717 Nº de citas: 6 [doi:10.1007/s12094-023-03177-7]

Aldea, M; Marinello, A; Duruisseaux, M; Zrafi, W; Conci, N; Massa, G; Metro, G; Monnet, I; Iranzo, PG; Tabbo, F; Bria, E; Guisier, F; Vasseur, D; Lindsay, CR; Ponce-Aix, S; Cousin, S; Citarella, F; Fallet, V; Minatta, JN; Eisert, A; Basile, HD; Audigier-Valette, C; Mezquita, L; Calles, A; Mountzios, G; Tagliamento, M; Masip, JR; Raimbourg, J; Terrisse, S; Russo, A; Cortinovis, D; Rochigneux, P; Pinato, DJ; Cortellini, A; Leonce, C; Gazzah, A; Ghigna, MR; Ferrara, R; Dall'Olio, FG; Passiglia, F; Ludovini, V; Barlesi, F; Felip, E; Planchard, D; Besse, B.

RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion

JOURNAL OF THORACIC ONCOLOGY. 2023; 18(5): 576-586 Nº de citas: 34 [doi:10.1016/j.jtho.2022.12.018]

Slamon, DJ; Fasching, PA; Hurvitz, S; Chia, S; Crown, J; Martin, M; Barrios, CH; Bardia, A; Im, SA; Yardley, DA; Untch, M; Huang, CS; Stroyakovskiy, D; Xu, BH; Moroose, RL; Loi, S; Visco, F; Bee-Munteanu, V; Afenjar, K; Fresco, R; Taran, T; Chakravartty, A; Zarate, JP; Lteif, A; Hortobagyi, GN.

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR+/HER2-early breast cancer

Therapeutic Advances in Medical Oncology. 2023; 15: Nº de citas: 64 [doi:10.1177/17588359231178125]

Sanfilippo, R; Hindi, N; Jurado, JC; Blay, JY; Lopez-Pousa, A; Italiano, A; Alvarez, R; Gutierrez, A; Rincon-Perez, I; Sangalli, C; Aguiar, JLP; Romero, J; Morosi, C; Sunyach, MP; Fabbroni, C; Romagosa, C; Ranchere-Vince, D; Dei Tos, AP; Casali, PG; Martin-Broto, J; Gronchi, A.

Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma A Nonrandomized Clinical Trial

JAMA Oncology. 2023; 9(5): 656-663 Nº de citas: 22 [doi:10.1001/jamaoncol.2023.0056]

Holmes, FA; Moy, B; Delaloge, S; Chia, SKL; Ejlertsen, B; Mansi, J; Iwata, H; Gnant, M; Buyse, M; Barrios, CH; Silovski, T; Separovic, R; Bashford, A; Zotano, AG; Denduluri, N; Patt, D; Gokmen, E; Gore, I; Ii, JWS; Loibl, S; Masuda, N; Tomasevic, Z; Petrakova, K; DiPrimeo, D; Wong, AL; Martin, M; Chan, ARE.

Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial

EUROPEAN JOURNAL OF CANCER. 2023; 184: 48-59 Nº de citas: 13 [doi:10.1016/j.ejca.2023.02.002]

Guerrero-Zotano, A; Belli, S; Zielinski, C; Gil-Gil, M; Fernandez-Serra, A; Ruiz-Borrego, M; Gil, EMC; Pascual, J; Munoz-Mateu, M; Bermejo, B; Vila, MM; Anton, A; Murillo, L; Nissenbaum, B; Liu, Y; Herranz, J; Fernandez-Garcia, D; Caballero, R; Lopez-Guerrero, JA; Bianco, R; Formisano, L; Turner, N; Martin, M.

CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2-Metastatic Breast Cancer

CLINICAL CANCER RESEARCH. 2023; 29(8): 1557-1568 Nº de citas: 30 [doi:10.1158/1078-0432.CCR-22-2206]

Canovas, MS; Garay, DF; Adoamnei, E; Garcia, EG; Robles, JL; Lavin, DC; de Castro, EM; Balea, BC; Fernandez, AG; Perez, IF; Arias, AF; Suarez, N; Verduguez, TQ; de Mena, ML; Rodriguez, L; Gutierrez, D; de Soiginie, AMMF; Adrian, SG; Perez, AIF; Heredia, MJD; Lerma, AM; Luque, R; Rubi, MM; Blanco, ABR; Escobar, IG; Mendiola, J; Martin, AJM.

Immune checkpoint inhibitor-associated thrombosis in patients with bladder and kidney cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group

CLINICAL & TRANSLATIONAL ONCOLOGY. 2023; 25(10): 3021-3031 Nº de citas: 3 [doi:10.1007/s12094-023-03171-z]

Hecht, JR; Raman, SS; Chan, A; Kalinsky, K; Baurain, JF; Jimenez, MM; Garcia, MM; Berger, MD; Lauer, UM; Khattak, A; Carrato, A; Zhang, Y; Liu, K; Cha, E; Keegan, A; Bhatta, S; Strassburg, CP; Roohullah, A.

Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases

Esmo Open. 2023; 8(2): Nº de citas: 5 [doi:10.1016/j.esmoop.2023.100884]